Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online July 16, 2007
Diabetes 56:2533-2540, 2007
DOI: 10.2337/db07-0007
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0007v1
56/10/2533    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, Q.-W.
Right arrow Articles by Rosen, E. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yan, Q.-W.
Right arrow Articles by Rosen, E. D.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Adipokine Lipocalin 2 Is Regulated by Obesity and Promotes Insulin Resistance

Qing-Wu Yan1, Qin Yang1, Nimesh Mody1, Timothy E. Graham1, Chung-Hsin Hsu1, Zhao Xu1, Nicholas E. Houstis2, Barbara B. Kahn1, and Evan D. Rosen1,2

1 Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Boston, Massachusetts
2 Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts

Address correspondence and reprint requests to Evan D. Rosen, MD, PhD, Division of Endocrinology, Diabetes, and Metabolism, Beth Israel Deaconess Medical Center, Boston, MA 02115. E-mail: erosen{at}bidmc.harvard.edu

Abbreviations: C/EBP, CCAAT/enhancer-binding protein; Dex, dexamethasone; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; PPAR, peroxisome proliferator–activated receptor; RBP, retinol binding protein; shRNA, short hairpin RNA; SVC, stromal vascular cell; SVF, stromal vascular factor; TNF, tumor necrosis factor; WAT, white adipose tissue

OBJECTIVE—We identified lipocalin 2 (Lcn2) as a gene induced by dexamethasone and tumor necrosis factor-{alpha} in cultured adipocytes. The purpose of this study was to determine how expression of Lcn2 is regulated in fat cells and to ascertain whether Lcn2 could be involved in metabolic dysregulation associated with obesity.

RESEARCH DESIGN AND METHODS—We examined Lcn2 expression in murine tissues and in 3T3-L1 adipocytes in the presence and absence of various stimuli. We used quantitative Western blotting to observe Lcn2 serum levels in lean and obese mouse models. To assess effects on insulin action, we used retroviral delivery of short hairpin RNA to reduce Lcn2 levels in 3T3-L1 adipocytes.

RESULTS—Lcn2 is highly expressed by fat cells in vivo and in vitro. Expression of Lcn2 is elevated by agents that promote insulin resistance and is reduced by thiazolidinediones. The expression of Lcn2 is induced during 3T3-L1 adipogenesis in a CCAAT/enhancer-binding protein–dependent manner. Lcn2 serum levels are elevated in multiple rodent models of obesity, and forced reduction of Lcn2 in 3T3-L1 adipocytes improves insulin action. Exogenous Lcn2 promotes insulin resistance in cultured hepatocytes.

CONCLUSIONS—Lcn2 is an adipokine with potential importance in insulin resistance associated with obesity.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.